Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes clinical relapse compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes radiologic relapse compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes withdrawal due to adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes health related quality of life compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASAs probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with placebo (very low certainty).
1 finding from 1 review
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical remission compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
1 finding from 1 review